Key result
Continuous intravenous epoprostenol successfully treated severe pulmonary hypertension in a patient following mitral valve replacement for mitral stenosis.
Case Report (n=1)
Continuous intravenous epoprostenol may be an effective treatment for severe pulmonary hypertension persisting after mitral valve replacement.
Answers are grounded in this paper and cite their sources.
May support epoprostenol in refractory post-MVR PH; hypothesis-generating case report requiring prospective validation.
Pulmonary hypertension frequently complicates mitral stenosis. Increased pulmonary artery pressure results from raised left atrial pressure, pulmonary arteriolar constriction, and obliterative changes in the pulmonary vascular bed, and usually responds to surgical relief of mitral stenosis. However, severe pulmonary hypertension may persist after surgical treatment of mitral stenosis. We describe a patient whose severe pulmonary hypertension following mitral valve replacement was treated successfully with continuous intravenous epoprostenol.
No takes yet. Share an insight, caveat, or question.
C. Gregory Elliott (2004) conducted a case report in Severe pulmonary arterial hypertension following mitral valve replacement for mitral stenosis (n=1). Continuous intravenous epoprostenol was evaluated on Successful treatment of severe pulmonary hypertension. Continuous intravenous epoprostenol successfully treated severe pulmonary hypertension in a patient following mitral valve replacement for mitral stenosis.
Synapse has enriched 10 related papers. Consider them for comparative context: